{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:00:08Z","timestamp":1793386808929,"version":"4.5.0"},"reference-count":130,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>Cytomegalovirus (CMV) is one of the most common infections occurring after solid organ transplantation. This high burden of disease, which incurs sizeable morbidity, may be worsening with the proportion of high-risk D+\/R\u2212 solid organ transplantation recipients increasing in some regions globally. Cohort studies continue to support either universal prophylaxis or preemptive therapy as effective prevention strategies. Letermovir prophylaxis was noninferior to valganciclovir in adult high-risk D+\/R\u2212 kidney transplant recipients with fewer drug-related adverse events in a recent clinical trial and has now been approved for such use in some regions. Maribavir preemptive therapy failed to demonstrate noninferiority when compared with valganciclovir in hematopoietic stem cell transplant recipients but looked promising for safety. Donor matching could be useful in prevention CMV disease with a survival advantage demonstrated in seronegative recipients waiting up to 30 mo for a seronegative kidney. Immune-guided prophylaxis resulted in fewer CMV infection episodes in lung transplant recipients when compared with fixed-duration prophylaxis in a recent clinical trial. For treatment of refractory or resistant CMV infection, maribavir was more efficacious and better tolerated when compared with investigator-initiated therapy in its registration trial for this condition. Further research regarding best treatment and prophylaxis of resistant or refractory CMV infection is needed to reflect best clinical practice choices. Optimal use of immune globulin or CMV-specific T cells for prevention or treatment of CMV disease remains undefined. Standardized definitions for the design of CMV clinical trials have been developed. In this review, we highlight recent updates in the field from data published since 2018.<\/jats:p>","DOI":"10.1097\/tp.0000000000004855","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:26Z","timestamp":1698624026000},"page":"884-897","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":34,"title":["What\u2019s New: Updates on Cytomegalovirus in Solid Organ Transplantation"],"prefix":"10.1097","volume":"108","author":[{"given":"Adam G.","family":"Stewart","sequence":"first","affiliation":[{"name":"Centre for Clinical Research, Faculty of Medicine, University of Queensland, Royal Brisbane and Women\u2019s Hospital Campus, Brisbane, QLD, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille N.","family":"Kotton","sequence":"additional","affiliation":[{"name":"Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/13696998.2022.2046388","article-title":"Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.","volume":"25","author":"Cheng","year":"2022","journal-title":"J Med Econ"},{"issue":"Suppl 3","key":"R2-20250604","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention, diagnosis and therapy.","volume":"13","author":"Kotton","year":"2013","journal-title":"Am J Transplant"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation.","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"issue":"Supplement_2","key":"R4-20250604","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.1897","article-title":"LB2307 safety and efficacy of letermovir (LET) versus valganciclovir (VGCV) for prevention of cytomegalovirus (CMV) disease in Kidney Transplant Recipients (KTRs): a phase 3 randomized study.","volume":"9","author":"Limaye","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation.","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"e242596","DOI":"10.1136\/bcr-2021-242596","article-title":"Delayed, transient and self-resolving neutropenia following COVID-19 pneumonia.","volume":"14","author":"Mank","year":"2021","journal-title":"BMJ Case Rep"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cid\/ciy549","article-title":"Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label phase I clinical trial.","volume":"68","author":"Smith","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials.","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40121-022-00746-1","article-title":"New insights on CMV management in solid organ transplant patients: prevention, treatment, and management of resistant\/refractory disease.","volume":"12","author":"Kotton","year":"2022","journal-title":"Infect Dis Ther"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"e00043","DOI":"10.1128\/CMR.00043-19","article-title":"Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation.","volume":"34","author":"Limaye","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1097\/TP.0000000000004352","article-title":"Increasing proportion of high-risk cytomegalovirus donor-positive\/recipient-negative serostatus in solid organ transplant recipients.","volume":"107","author":"Imlay","year":"2023","journal-title":"Transplantation"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"e704","DOI":"10.1097\/TXD.0000000000001147","article-title":"Geographic distribution of cytomegalovirus serology in kidney and pancreas transplant recipients in the United States.","volume":"7","author":"Jorgenson","year":"2021","journal-title":"Transplant Direct"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/ajt.14195","article-title":"Transplant infectious diseases: a review of the scientific registry of transplant recipients published data.","volume":"17","author":"Kotton","year":"2017","journal-title":"Am J Transplant"},{"issue":"Suppl 2","key":"R15-20250604","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ajt.16982","article-title":"OPTN\/SRTR 2020 annual data report: kidney.","volume":"22","author":"Lentine","year":"2022","journal-title":"Am J Transplant"},{"issue":"Suppl 2","key":"R16-20250604","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/ajt.16979","article-title":"OPTN\/SRTR 2020 annual data report: pancreas.","volume":"22","author":"Kandaswamy","year":"2022","journal-title":"Am J Transplant"},{"issue":"Suppl 2","key":"R17-20250604","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/ajt.16978","article-title":"OPTN\/SRTR 2020 annual data report: liver.","volume":"22","author":"Kwong","year":"2022","journal-title":"Am J Transplant"},{"issue":"Suppl 2","key":"R18-20250604","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/ajt.16977","article-title":"OPTN\/SRTR 2020 annual data report: heart.","volume":"22","author":"Colvin","year":"2022","journal-title":"Am J Transplant"},{"issue":"Suppl 2","key":"R19-20250604","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/ajt.16991","article-title":"OPTN\/SRTR 2020 annual data report: lung.","volume":"22","author":"Valapour","year":"2022","journal-title":"Am J Transplant"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1097\/TP.0000000000004615","article-title":"Cytomegalovirus high-risk kidney transplant recipients show no difference in long-term outcomes following preemptive versus prophylactic management.","volume":"107","author":"Blom","year":"2023","journal-title":"Transplantation"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation.","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial.","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/TP.0000000000003887","article-title":"The clinical and economic benefit of CMV matching in kidney transplant: a decision analysis.","volume":"106","author":"Axelrod","year":"2022","journal-title":"Transplantation"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1111\/ajt.15976","article-title":"Cytomegalovirus serologic matching in deceased donor kidney allocation optimizes high- and low-risk (D+R and DR\/-) profiles and does not adversely affect transplant rates.","volume":"20","author":"Lockridge","year":"2020","journal-title":"Am J Transplant"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"100669","DOI":"10.1016\/j.trre.2021.100669","article-title":"Human genetic polymorphisms and risk of viral infection after solid organ transplantation.","volume":"36","author":"Redondo","year":"2022","journal-title":"Transplant Rev (Orlando)"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3389\/fgene.2019.00616","article-title":"Host genetics of cytomegalovirus pathogenesis.","volume":"10","author":"Sezgin","year":"2019","journal-title":"Front Genet"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"7094","DOI":"10.4049\/jimmunol.177.10.7094","article-title":"Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells.","volume":"177","author":"Boehme","year":"2006","journal-title":"J Immunol"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/ajt.13107","article-title":"Association between individual and combined SNPs in genes related to innate immunity and incidence of CMV infection in seropositive kidney transplant recipients.","volume":"15","author":"Fern\u00e1ndez-Ruiz","year":"2015","journal-title":"Am J Transplant"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/ajt.15160","article-title":"Impact of MBL2 gene polymorphisms on the risk of infection in solid organ transplant recipients: a systematic review and meta-analysis.","volume":"19","author":"Fern\u00e1ndez-Ruiz","year":"2019","journal-title":"Am J Transplant"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"929995","DOI":"10.3389\/fimmu.2022.929995","article-title":"Influence of single-nucleotide polymorphisms in TLR3 (rs3775291) and TLR9 (rs352139) on the risk of CMV infection in kidney transplant recipients.","volume":"13","author":"Redondo","year":"2022","journal-title":"Front Immunol"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1086\/514339","article-title":"Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after Liver Transplantation.","volume":"44","author":"Kijpittayarit","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/infdis\/jiu557","article-title":"Influence of IFNL3\/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation.","volume":"211","author":"Manuel","year":"2015","journal-title":"J Infect Dis"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.3389\/fimmu.2019.02871","article-title":"The Aquaporin 5-1364A\/C promoter polymorphism is associated with cytomegalovirus infection risk in kidney transplant recipients.","volume":"10","author":"Rahmel","year":"2019","journal-title":"Front Immunol"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1111\/jcpt.13775","article-title":"Management of drug-induced neutropenia, thrombocytopenia, and anaemia after solid organ transplantation: a comprehensive review.","volume":"47","author":"Baradaran","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"e13295","DOI":"10.1111\/ctr.13295","article-title":"Two cases of tacrolimus-induced neutropenia: A probably under-diagnosed cause of neutropenia after solid-organ transplantation.","volume":"32","author":"Cl\u00e9ment","year":"2018","journal-title":"Clin Transplant"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1034\/j.1399-0012.2003.00026.x","article-title":"The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation.","volume":"17","author":"Pelletier","year":"2003","journal-title":"Clin Transplant"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1111\/ajt.16714","article-title":"Febrile neutropenia after kidney transplantation.","volume":"21","author":"Dube","year":"2021","journal-title":"Am J Transplant"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ajt.15581","article-title":"Lung transplant outcomes are influenced by severity of neutropenia and granulocyte colony-stimulating factor treatment.","volume":"20","author":"Tague","year":"2020","journal-title":"Am J Transplant"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"e13634","DOI":"10.1111\/tid.13634","article-title":"Factors associated with neutropenia post heart transplantation.","volume":"23","author":"Chow","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"e14583","DOI":"10.1111\/ctr.14583","article-title":"Outcomes among CMV-mismatched and highly sensitized kidney transplants recipients who develop neutropenia.","volume":"36","author":"Brar","year":"2022","journal-title":"Clin Transplant"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/TP.0b013e31821c1e70","article-title":"Poor outcomes associated with neutropenia after kidney transplantation: analysis of United States Renal Data System.","volume":"92","author":"Hurst","year":"2011","journal-title":"Transplantation"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/infdis\/166.6.1228","article-title":"Recovery from cytomegalovirus infection is associated with activation of peripheral blood lymphocytes.","volume":"166","author":"van den Berg","year":"1992","journal-title":"J Infect Dis"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41598-020-80790-4","article-title":"Post-transplant absolute lymphocyte count predicts early cytomegalovirus infection after heart transplantation.","volume":"11","author":"Yoon","year":"2021","journal-title":"Sci Rep"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"e3797","DOI":"10.1093\/cid\/ciaa1800","article-title":"Association between lymphopenia at 1 month posttransplant and infectious outcomes or death in heart transplant recipients.","volume":"73","author":"Perry","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/cid\/ciy295","article-title":"Absolute lymphocyte count: a predictor of recurrent cytomegalovirus disease in solid organ transplant recipients.","volume":"67","author":"Gardiner","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"ofy230","DOI":"10.1093\/ofid\/ofy230","article-title":"Absolute lymphocyte count thresholds: a simple, readily available tool to predict the risk of cytomegalovirus infection after transplantation.","volume":"5","author":"Meesing","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"e13489","DOI":"10.1111\/tid.13489","article-title":"Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: is there a \u201cSafe Corridor\u201d after kidney transplantation?","volume":"23","author":"El Helou","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"e13577","DOI":"10.1111\/tid.13577","article-title":"The burden of cytomegalovirus infection remains high in high-risk kidney transplant recipients despite six-month valganciclovir prophylaxis.","volume":"23","author":"R\u00e4ih\u00e4","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.healun.2008.02.002","article-title":"High incidence of cytomegalovirus disease in D+\/R heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis.","volume":"27","author":"Gupta","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"e0171621","DOI":"10.1128\/jcm.01716-21","article-title":"Utility of cytomegalovirus cell-mediated immunity assays in solid organ transplantation.","volume":"60","author":"Hall","year":"2022","journal-title":"J Clin Microbiol"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/TP.0000000000002454","article-title":"A randomized study of quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation.","volume":"103","author":"Westall","year":"2019","journal-title":"Transplantation"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.healun.2022.05.004","article-title":"Real-world experience of quantiferon-CMV directed prophylaxis in lung transplant recipients.","volume":"41","author":"Gardiner","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.arbres.2021.10.002","article-title":"Assessment of Quantiferon-CMV and Immuknow assays in CMV-seropositive lung transplant recipients to stratify risk of CMV infection.","volume":"58","author":"Monforte","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"R55-20250604","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/infdis\/jiaa727","article-title":"CMV-specific cell-mediated immunity predicts a high level of CMV replication after prophylaxis withdrawal in lung transplant recipients.","volume":"224","author":"Donadeu","year":"2021","journal-title":"J Infect Dis"},{"key":"R56-20250604","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.healun.2020.01.001","article-title":"QuantiFERON-CMV guided virostatic prophylaxis after heart transplantation.","volume":"39","author":"Poglajen","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"R57-20250604","doi-asserted-by":"crossref","first-page":"e01040","DOI":"10.1128\/JCM.01040-17","article-title":"Monitoring of cytomegalovirus (CMV)-specific cell-mediated immunity in heart transplant recipients: clinical utility of the QuantiFERON-CMV assay for management of posttransplant CMV infection.","volume":"56","author":"Chiereghin","year":"2018","journal-title":"J Clin Microbiol"},{"key":"R58-20250604","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/cid\/ciab574","article-title":"Immunoguided discontinuation of prophylaxis for cytomegalovirus disease in kidney transplant recipients treated with antithymocyte globulin: a randomized clinical trial.","volume":"74","author":"P\u00e1ez-Vega","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R59-20250604","doi-asserted-by":"crossref","first-page":"893232","DOI":"10.3389\/fcimb.2022.893232","article-title":"QuantiFERON-cytomegalovirus assay for prediction of cytomegalovirus viremia in kidney transplant recipients: study from high cytomegalovirus seroprevalence country.","volume":"12","author":"Pongsakornkullachart","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"R60-20250604","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12879-018-3075-z","article-title":"Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.","volume":"18","author":"Deborska-Materkowska","year":"2018","journal-title":"BMC Infect Dis"},{"key":"R61-20250604","first-page":"554","article-title":"Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia.","volume":"50","author":"Thompson","year":"2018","journal-title":"Pathology (Phila)"},{"key":"R62-20250604","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3904\/kjim.2017.318","article-title":"Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant.","volume":"35","author":"Kim","year":"2020","journal-title":"Korean J Intern Med"},{"key":"R63-20250604","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients.","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transplant"},{"key":"R64-20250604","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/tri.13110","article-title":"Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study.","volume":"31","author":"Banas","year":"2018","journal-title":"Transpl Int"},{"key":"R65-20250604","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/vaccines9020088","article-title":"Comparison of three cellular assays to predict the course of CMV infection in liver transplant recipients.","volume":"9","author":"Gliga","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"R66-20250604","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.trim.2018.09.004","article-title":"CMV specific T cell immunity predicts early viremia after liver transplantation.","volume":"51","author":"Shin","year":"2018","journal-title":"Transpl Immunol"},{"key":"R67-20250604","doi-asserted-by":"crossref","first-page":"1753466620981851","DOI":"10.1177\/1753466620981851","article-title":"Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice.","volume":"14","author":"Solidoro","year":"2020","journal-title":"Ther Adv Respir Dis"},{"key":"R68-20250604","doi-asserted-by":"crossref","first-page":"e13550","DOI":"10.1111\/tid.13550","article-title":"Evaluation of Quantiferon-monitor as a biomarker of immunosuppression and predictor of infection in lung transplant recipients.","volume":"23","author":"Gardiner","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R69-20250604","doi-asserted-by":"crossref","first-page":"e14858","DOI":"10.1111\/ctr.14858","article-title":"Immune cell function assay and T lymphocyte counts lack association with rejection or infection in pediatric heart transplant recipients.","volume":"37","author":"Chen","year":"2023","journal-title":"Clin Transplant"},{"key":"R70-20250604","doi-asserted-by":"crossref","first-page":"15490","DOI":"10.1038\/s41598-018-33909-7","article-title":"Early post-transplant torquetenovirus viremia predicts cytomegalovirus reactivations in solid organ transplant recipients.","volume":"8","author":"Maggi","year":"2018","journal-title":"Sci Rep"},{"key":"R71-20250604","doi-asserted-by":"crossref","first-page":"104871","DOI":"10.1016\/j.jcv.2021.104871","article-title":"Torque teno virus loads after kidney transplantation predict allograft rejection but not viral infection.","volume":"140","author":"van Rijn","year":"2021","journal-title":"J Clin Virol"},{"key":"R72-20250604","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/j.healun.2021.01.951","article-title":"Torque teno virus does not predict cytomegalovirus infection post-lung transplantation.","volume":"40","author":"Hirji","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"R73-20250604","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/lt.25374","article-title":"Torque teno virus is associated with the state of immune suppression early after liver transplantation.","volume":"25","author":"Ruiz","year":"2019","journal-title":"Liver Transpl"},{"key":"R74-20250604","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jiy306","article-title":"Quantification of torque teno virus viremia as a prospective biomarker for infectious disease in kidney allograft recipients.","volume":"218","author":"Strassl","year":"2018","journal-title":"J Infect Dis"},{"key":"R75-20250604","doi-asserted-by":"crossref","first-page":"e153175","DOI":"10.1172\/jci.insight.153175","article-title":"NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant.","volume":"6","author":"Pickering","year":"2021","journal-title":"JCI Insight"},{"key":"R76-20250604","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1111\/ajt.17147","article-title":"A consensus conference to define the utility of advanced infectious disease diagnostics in solid organ transplant recipients.","volume":"22","author":"Azar","year":"2022","journal-title":"Am J Transplant"},{"key":"R77-20250604","doi-asserted-by":"crossref","first-page":"10332","DOI":"10.3389\/ti.2022.10332","article-title":"Cytomegalovirus management in solid organ transplant recipients: a pre-COVID-19 survey from the working group of the European Society for organ transplantation.","volume":"35","author":"Grossi","year":"2022","journal-title":"Transpl Int"},{"issue":"Suppl 1","key":"R78-20250604","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/infdis\/jiz493","article-title":"Advances in the development of therapeutics for cytomegalovirus infections.","volume":"221","author":"Acosta","year":"2020","journal-title":"J Infect Dis"},{"key":"R79-20250604","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"R80-20250604","first-page":"e1","article-title":"Gaining consensus around patient risk groups and prognostic profiles to guide CMV management among patients with solid organ transplant: insights from a Delphi panel with SOT experts.","volume":"37","author":"Pednekar","year":"4905","journal-title":"Clin Transplant"},{"key":"R81-20250604","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/FTD.0000000000000925","article-title":"Therapeutic drug monitoring of ganciclovir: where are we?","volume":"44","author":"M\u00e4rtson","year":"2022","journal-title":"Ther Drug Monit"},{"key":"R82-20250604","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/jac\/dkab195","article-title":"Ganciclovir therapeutic drug monitoring in transplant recipients.","volume":"76","author":"M\u00e4rtson","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R83-20250604","doi-asserted-by":"crossref","first-page":"e13207","DOI":"10.1111\/tid.13207","article-title":"Clinical predictors of progression and clearance of low-level CMV DNAemia in solid organ transplant recipients.","volume":"22","author":"Natori","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"R84-20250604","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jcv.2017.12.011","article-title":"Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.","volume":"99-100","author":"Noble","year":"2018","journal-title":"J Clin Virol"},{"key":"R85-20250604","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1600-6143.2012.04087.x","article-title":"Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy.","volume":"12","author":"Atabani","year":"2012","journal-title":"Am J Transplant"},{"key":"R86-20250604","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12879-022-07123-w","article-title":"Incidence of Cytomegalovirus disease and viral replication kinetics in seropositive Liver Transplant recipients managed under preemptive therapy in a tertiary-care center in Mexico City: a retrospective cohort study.","volume":"22","author":"Fern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"BMC Infect Dis"},{"key":"R87-20250604","doi-asserted-by":"crossref","first-page":"e12852","DOI":"10.1111\/tid.12852","article-title":"Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: a single-center study.","volume":"20","author":"Pierce","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"R88-20250604","doi-asserted-by":"crossref","first-page":"e13521","DOI":"10.1111\/tid.13521","article-title":"Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection.","volume":"23","author":"Mehta Steinke","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R89-20250604","doi-asserted-by":"crossref","first-page":"e13931","DOI":"10.1111\/tid.13931","article-title":"Impact of antimetabolite discontinuation following cytomegalovirus or BK polyoma virus infection in kidney transplant recipients.","volume":"24","author":"Dubrawka","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"R90-20250604","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation.","volume":"17","author":"Kumar","year":"2017","journal-title":"Am J Transplant"},{"key":"R91-20250604","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/covid1010010","article-title":"A new viral coinfection: SARS-CoV-2 pneumonia and cytomegalovirus pneumonitis in a renal transplant recipient.","volume":"1","author":"Shaikh","year":"2021","journal-title":"COVID"},{"key":"R92-20250604","doi-asserted-by":"crossref","first-page":"e13455","DOI":"10.1111\/tid.13455","article-title":"Iranian kidney transplant recipients with COVID-19 infection: clinical outcomes and cytomegalovirus coinfection.","volume":"23","author":"Molaei","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R93-20250604","doi-asserted-by":"crossref","first-page":"e7046","DOI":"10.1002\/ccr3.7046","article-title":"Co-infection of coronavirus disease 19 and cytomegalovirus in a kidney transplant recipient.","volume":"11","author":"Farrokhnia","year":"2023","journal-title":"Clin Case Reports"},{"key":"R94-20250604","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/transplantology3010010","article-title":"Are CMV and SARS-CoV-2 infections mutual risk factors in kidney transplant recipients?","volume":"3","author":"Swist","year":"2022","journal-title":"Transplantology"},{"key":"R95-20250604","doi-asserted-by":"crossref","first-page":"e1344","DOI":"10.1097\/TXD.0000000000001344","article-title":"CMV infection following mRNA SARS-CoV-2 vaccination in solid organ transplant recipients.","volume":"8","author":"Chakravorty","year":"2022","journal-title":"Transplant Direct"},{"issue":"Suppl 3","key":"R96-20250604","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/TP.0000000000001095","article-title":"The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV.","volume":"100","author":"Carbone","year":"2016","journal-title":"Transplantation"},{"key":"R97-20250604","doi-asserted-by":"crossref","first-page":"e13560","DOI":"10.1111\/ctr.13560","article-title":"Clinical outcomes of polyvalent immunoglobulin use in solid organ transplant recipients: a systematic review and meta-analysis.","volume":"33","author":"Bourassa-Blanchette","year":"2019","journal-title":"Clin Transplant"},{"issue":"Suppl 3","key":"R98-20250604","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/TP.0000000000001096","article-title":"Cytomegalovirus hyper immunoglobulin for CMV prophylaxis in thoracic transplantation.","volume":"100","author":"Rea","year":"2016","journal-title":"Transplantation"},{"key":"R99-20250604","doi-asserted-by":"crossref","first-page":"661","DOI":"10.12659\/AOT.894694","article-title":"Cytomegalovirus immunoglobulin for prophylaxis and treatment of cytomegalovirus infection in the (Val)Ganciclovir era: a single-center experience.","volume":"20","author":"Lopez Garcia-Gallo","year":"2015","journal-title":"Ann Transplant"},{"key":"R100-20250604","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/microorganisms11010032","article-title":"Evaluation of two different CMV-immunoglobulin regimens for combined CMV prophylaxis in high-risk patients following lung transplant.","volume":"11","author":"Mora","year":"2022","journal-title":"Microorganisms"},{"key":"R101-20250604","doi-asserted-by":"crossref","first-page":"e781","DOI":"10.1097\/TXD.0000000000001236","article-title":"Stimulatory effect of CMV immunoglobulin on innate immunity and on the immunogenicity of CMV antigens.","volume":"7","author":"Deml","year":"2021","journal-title":"Transplant Direct"},{"key":"R102-20250604","doi-asserted-by":"crossref","first-page":"e13733","DOI":"10.1111\/tid.13733","article-title":"Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review.","volume":"24","author":"Santhanakrishnan","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"R103-20250604","doi-asserted-by":"crossref","first-page":"623178","DOI":"10.3389\/fimmu.2020.623178","article-title":"Case report: management of a multidrug-resistant CMV-strain in a renal transplant recipient by high-dose CMV-specific immunoglobulins, modulation in immunosuppression, and induction of CMV-specific cellular immunity.","volume":"11","author":"Wiening","year":"2020","journal-title":"Front Immunol"},{"key":"R104-20250604","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.transproceed.2021.02.001","article-title":"Successful treatment of UL97 mutation ganciclovir-resistant cytomegalovirus viremia in a renal transplant recipient with letermovir and adjunct hyperimmune cytomegalovirus immunoglobulin: A case report.","volume":"53","author":"Pearston","year":"2021","journal-title":"Transplant Proc"},{"key":"R105-20250604","doi-asserted-by":"crossref","first-page":"e0139322","DOI":"10.1128\/spectrum.01393-22","article-title":"Neutralization epitopes in trimer and pentamer complexes recognized by potent cytomegalovirus-neutralizing human monoclonal antibodies.","volume":"10","author":"Ai","year":"2022","journal-title":"Microbiol Spectr"},{"key":"R106-20250604","doi-asserted-by":"crossref","first-page":"e01108","DOI":"10.1128\/AAC.01108-17","article-title":"Pharmacokinetics and exposure-response analysis of RG7667, a combination of two anticytomegalovirus monoclonal antibodies, in a phase 2a randomized trial to prevent cytomegalovirus infection in high-risk kidney transplant recipients.","volume":"62","author":"Deng","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R107-20250604","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.5","article-title":"Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation.","volume":"4","author":"Holmes-Liew","year":"2015","journal-title":"Clin Transl Immunol"},{"key":"R108-20250604","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1002\/hsr2.322","article-title":"Immunotherapy with adoptive cytomegalovirus-specific T cells transfer: Summarizing latest gene engineering techniques.","volume":"4","author":"Mehdizadeh","year":"2021","journal-title":"Health Sci Rep"},{"key":"R109-20250604","doi-asserted-by":"crossref","first-page":"101539","DOI":"10.1016\/j.trim.2022.101539","article-title":"Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells.","volume":"71","author":"Ivana","year":"2022","journal-title":"Transpl Immunol"},{"key":"R110-20250604","doi-asserted-by":"crossref","first-page":"905","DOI":"10.34067\/KID.0001572021","article-title":"Role of virus-specific T cell therapy for cytomegalovirus and BK infections in kidney transplant recipients.","volume":"2","author":"Parajuli","year":"2021","journal-title":"Kidney360"},{"key":"R111-20250604","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/ajt.13023","article-title":"Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient.","volume":"15","author":"Macesic","year":"2015","journal-title":"Am J Transplant"},{"key":"R112-20250604","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3390\/microorganisms9040684","article-title":"Successful use of heterologous CMV-reactive T lymphocyte to treat severe refractory cytomegalovirus (CMV) infection in a liver transplanted patient: correlation of the host antiviral immune reconstitution with CMV viral load and CMV miRNome.","volume":"9","author":"Miele","year":"2021","journal-title":"Microorganisms"},{"key":"R113-20250604","doi-asserted-by":"crossref","first-page":"657144","DOI":"10.3389\/fimmu.2021.657144","article-title":"Is it feasible to use CMV-specific T-cell adoptive transfer as treatment against infection in SOT recipients?","volume":"12","author":"Garc\u00eda-R\u00edos","year":"2021","journal-title":"Front Immunol"},{"key":"R114-20250604","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1016\/j.transproceed.2018.08.009","article-title":"Risk Factors for the development of cytomegalovirus resistance in solid organ transplantation: a retrospective case-control study.","volume":"50","author":"Sandkovsky","year":"2018","journal-title":"Transplant Proc"},{"key":"R115-20250604","doi-asserted-by":"crossref","first-page":"ofab462","DOI":"10.1093\/ofid\/ofab462","article-title":"Development and dynamics of cytomegalovirus UL97 ganciclovir resistance mutations in transplant recipients detected by next-generation sequencing.","volume":"8","author":"Lodding","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"R116-20250604","doi-asserted-by":"crossref","first-page":"104616","DOI":"10.1016\/j.antiviral.2019.104616","article-title":"Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.","volume":"172","author":"Chou","year":"2019","journal-title":"Antiviral Res"},{"key":"R117-20250604","doi-asserted-by":"crossref","first-page":"e0019122","DOI":"10.1128\/spectrum.00191-22","article-title":"Assessment of UL56 mutations before letermovir therapy in refractory cytomegalovirus transplant recipients.","volume":"10","author":"Santos Bravo","year":"2022","journal-title":"Microbiol Spectr"},{"key":"R118-20250604","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection.","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"R119-20250604","doi-asserted-by":"crossref","first-page":"e13687","DOI":"10.1111\/tid.13687","article-title":"Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients.","volume":"23","author":"Linder","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R120-20250604","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/cid\/ciaa1713","article-title":"Letermovir and maribavir for the treatment and prevention of cytomegalovirus infection in solid organ and stem cell transplant recipients.","volume":"73","author":"Imlay","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R121-20250604","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am J Transplant"},{"key":"R122-20250604","doi-asserted-by":"crossref","first-page":"e13515","DOI":"10.1111\/tid.13515","article-title":"Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.","volume":"23","author":"Hofmann","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R123-20250604","doi-asserted-by":"crossref","first-page":"e14401","DOI":"10.1111\/ctr.14401","article-title":"Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.","volume":"35","author":"Rho","year":"2021","journal-title":"Clin Transplant"},{"key":"R124-20250604","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study.","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R126-20250604","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1017\/ice.2020.203","article-title":"The development and implementation of stewardship initiatives to optimize the prevention and treatment of cytomegalovirus infection in solid-organ transplant recipients.","volume":"41","author":"Jorgenson","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R127-20250604","doi-asserted-by":"crossref","first-page":"e13864","DOI":"10.1111\/tid.13864","article-title":"Cytomegalovirus antiviral stewardship in solid organ transplant recipients: a new gold standard.","volume":"24","author":"Jorgenson","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"R128-20250604","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOT.0000000000001032","article-title":"CMV antiviral stewardship: navigating obstacles to facilitate target attainment.","volume":"28","author":"Jorgenson","year":"2023","journal-title":"Curr Opin Organ Transplant"},{"key":"R129-20250604","doi-asserted-by":"crossref","first-page":"e12991","DOI":"10.1111\/tid.12991","article-title":"A pharmacist-driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in ambulatory solid organ transplant recipients.","volume":"20","author":"Wang","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"R130-20250604","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1016\/j.vaccine.2018.02.089","article-title":"Vaccination against the human cytomegalovirus.","volume":"37","author":"Plotkin","year":"2019","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"R131-20250604","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1093\/infdis\/jiz389","article-title":"The development of therapeutics for the treatment and prevention of CMV disease in the transplant population: a regulatory perspective.","volume":"221","author":"Hodowanec","year":"2020","journal-title":"J Infect Dis"},{"key":"R132-20250604","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR).","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R133-20250604","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials.","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:07:00Z","timestamp":1749046020000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004855","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,30]]}}}